迷幻藥市場－全球產業規模、佔有率、趨勢、機會和預測：按藥物類型、應用、分銷管道、地區和競爭格局分類，2021-2031年

全球迷幻藥市場預計將從 2025 年的 46.2 億美元大幅成長至 2031 年的 84.6 億美元，複合年成長率為 10.61%。

該市場的核心在於開發和商業化諸如裸蓋菇素和MDMA等精神活性化合物，用於在受控的臨床環境中治療精神疾病。主要成長要素包括全球難治性憂鬱症和創傷後壓力症候群（PTSD）盛行率的上升，以及現有藥物療法的不足。這項迫切的醫療需求正促使政府增加撥款，機構加大對臨床研究的支持。例如，多學科迷幻藥研究協會（MAPS）的一份報告指出，美國國防部計劃到2025年撥款約1000萬美元，用於加速MDMA治療創傷後壓力症候群（PTSD）的研究，這表明該領域日益受到重視。

然而，嚴格的監管要求對市場的快速擴張構成重大障礙。複雜的核准流程需要大量的安全數據，並建立專門的藥物監管設施，這使得規模化生產和商業性滲透都面臨挑戰。此外，對特定治療師進行培訓以實施這些治療，可能會造成物流瓶頸，延誤患者就醫，並阻礙新參與企業產生收入。

市場促進因素

迷幻藥物研發的資本投入不斷增加，正強勁推動後期臨床計畫的進展。這是因為生物製藥公司正在籌集大量資金，以應對成本高昂的醫藥品認證過程。這筆資金注入對於維持長期的三期臨床試驗以及建立未來產品上市所需的商業基礎設施至關重要。例如， 指南針 Pathways公司於2025年1月宣布，預計將透過承銷公開發行籌集約1.5億美元。這筆資金將用於一項正在進行的針對難治性憂鬱症的第三期臨床試驗。如此雄厚的資金實力使相關人員能夠降低藥物研發過程中固有的風險，並加速從實驗研究到廣泛適用的治療方案的轉換。

同時，隨著有利的監管改革和非刑事化措施的推進，市場格局正在轉變，核准流程更加清晰，機構接受度也隨之提高。監管機構越來越重視透明度，並加強與行業贊助商的合作，以解決安全問題並改善試驗設計。根據《精神病學時報》報道，2025年9月，美國食品藥物管理局（FDA）針對一項被駁回的MDMA輔助療法申請發布了“完整回复函”，此舉旨在提高未來申請的監管透明度。聯邦政府參與度的提高進一步凸顯了這種不斷變化的支持環境。據羅斯·希爾（Rose Hill）稱，2025年標誌著政府對該領域的支持迎來了一個歷史性的轉折點，美國退伍軍人事務部和國立衛生研究院直接撥款津貼迷幻藥研究。

市場挑戰

嚴格的法規結構是全球迷幻藥市場成長的主要障礙。精神藥物的核准流程極為嚴格，需要進行大規模的III期臨床試驗，以建立符合FDA等監管機構高標準的安全性及有效性。與傳統藥物不同，迷幻療法通常需要藥物給藥和心理治療相結合的方案，這使得監管機構難以評估藥物的獨立療效。這種複雜性導致研發週期延長，監管後果難以預測，增加了相關人員的財務風險，並延遲了上市產品的推出，直接阻礙了市場成長。

這些監管壁壘參與企業帶來了沉重的營運和財務負擔，往往導致大規模重組和裁員。監管機構強制要求提供額外的安全數據，而由此產生的巨額成本會耗盡資源，阻礙研發進度。例如，2025年，迷幻藥研究多學科協會（MAPS）報告稱，在其新藥認證的MDMA輔助療法申請被監管機構駁回後，其公益子公司被迫裁員75%，以確保重啟臨床試驗的資金。此類裁員凸顯了嚴格的監管措施如何迅速耗盡關鍵機構的資金，從而凍結可擴展治療方法的研發管線，並阻礙未來機構對該領域的投資。

市場趨勢

一種向短效迷幻化合物的新轉變正迅速成為一股重要趨勢，旨在克服第一代治療方法固有的可擴展性限制，這些療法需要長期監測。透過開發半衰期短的分子，研究人員正在創造可在標準臨床實踐時間內給藥的治療方法，從而降低人事費用並提高患者處理能力。這種創新體現在新型血清素能前藥的最新臨床進展中，這些前前驅藥物旨在快速緩解症狀，而無需像傳統裸蓋菇素那樣進行6-8小時的療程。 2025年8月，Reunion Neuroscience公佈了其RECONNECT II期臨床試驗的正面初步結果。該公司研發的短效化合物RE104在第7天顯示出憂鬱症嚴重程度評分顯著降低23.0分，凸顯了其更有效率的治療潛力。

同時，大型製藥企業的策略性進入正在重塑競爭格局，使該領域從生物技術公司主導的局面轉變為與現有產業巨頭日益融合的局面。大型製藥企業正透過高價值的收購和授權協議逐步展現其在該領域的實力，力求利用其全球商業化能力開發下一代神經可塑性藥物。這一趨勢標誌著市場日趨成熟，現有企業正積極收購有前景的資產，以實現其神經科學產品組合的多元化。根據Fierce Biotech報道，艾伯維(AbbVie)於2025年8月達成協議，以高達12億美元的價格收購吉爾伽美甚(Gilgamesh)的迷幻藥項目，這代表了大型製藥企業對該治療領域前所未有的投入。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球迷幻藥市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 藥物類型（麥角酸二乙醯胺、γ-羥基丁酸、氯胺酮、裸蓋菇素、其他）
  • 依應用領域（難治性憂鬱症、鴉片類藥物成癮、創傷後壓力症候群、嗜睡症、恐慌症等）
  • 分銷通路（醫院藥局、零售藥局、網路藥局）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美迷幻藥市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲迷幻藥市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區迷幻藥市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲迷幻藥市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲迷幻藥市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球迷幻藥市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Jazz Pharmaceuticals PLC
• NeonMind Biosciences Inc.
• Cybin Inc.
• Pfizer Inc.
• Numinus Wellness Inc.
• Mind Medicine Inc.
• PharmaTher Holdings Ltd
• NRX Pharmaceuticals Inc.
• Seelos Therapeutics Inc.
• Revive Therapeutics Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Psychedelic Drug Market is projected to expand significantly, rising from USD 4.62 Billion in 2025 to USD 8.46 Billion by 2031, demonstrating a 10.61% compound annual growth rate. This market centers on developing and commercializing psychoactive compounds like psilocybin and MDMA for use in controlled clinical environments to address mental health conditions. Key growth drivers include the rising global incidence of treatment-resistant depression and PTSD, coupled with the insufficient effectiveness of existing pharmacotherapies. This critical medical necessity has stimulated greater government funding and institutional backing for clinical research, exemplified by the Multidisciplinary Association for Psychedelic Studies reporting that the Department of Defense allocated nearly $10 million in 2025 to expedite MDMA research for post-traumatic stress disorder, underscoring the sector's increasing validation.

Nevertheless, stringent regulatory requirements pose a considerable hurdle to rapid market expansion. The intricate approval process demands extensive safety data and the establishment of specialized facilities for supervised drug administration, which complicates both scalability and commercial adoption. Furthermore, the requirement for specific therapist training to deliver these treatments creates a logistical bottleneck, potentially delaying patient access and impeding revenue generation for primary market participants.

Market Driver

Elevated capital investment in psychedelic drug development is vigorously propelling late-stage clinical programs forward, as biopharmaceutical companies secure substantial funding essential for navigating the costly drug approval pathway. This infusion of capital is crucial for sustaining protracted Phase 3 trials and constructing the necessary commercial infrastructure for upcoming product launches. For instance, Compass Pathways announced in January 2025 that an underwritten offering was expected to yield approximately $150 million in gross proceeds, designated for their ongoing pivotal Phase 3 trials targeting treatment-resistant depression. Such financial robustness enables stakeholders to mitigate inherent drug development risks and expedite the transition from experimental research to broadly applicable therapeutic solutions.

Concurrently, favorable regulatory reforms and decriminalization initiatives are transforming the market landscape by establishing clearer approval pathways and fostering greater institutional acceptance. Regulatory authorities are increasingly prioritizing transparency and collaboration with industry sponsors to address safety concerns and refine study designs. According to Psychiatric Times, in September 2025, the FDA publicly released the Complete Response Letter for a rejected MDMA-assisted therapy application, a strategic move aimed at providing enhanced regulatory clarity for subsequent submissions. This evolving supportive environment is further highlighted by increased federal engagement; Rose Hill reported that in 2025, the Department of Veterans Affairs and the National Institutes of Health issued direct grants for psychedelic studies, marking a historic shift in government endorsement of this sector.

Market Challenge

Stringent regulatory frameworks represent a primary obstacle to the growth of the Global Psychedelic Drug Market. The approval process for psychoactive substances is exceptionally rigorous, demanding extensive Phase 3 clinical trials to establish safety and efficacy profiles that satisfy the high standards of agencies such as the FDA. Unlike conventional pharmaceuticals, psychedelic therapies frequently necessitate a combined protocol of drug administration and psychotherapy, which complicates the regulatory evaluation of the drug's isolated effect. This complexity results in extended development timelines and unpredictable regulatory outcomes, directly hindering market growth by elevating financial risks for stakeholders and delaying the launch of commercial products.

These regulatory impediments impose severe operational and financial burdens on market participants, often leading to significant organizational restructuring or downsizing. The substantial cost of generating the additional safety data mandated by regulators can deplete resources and impede progress. For example, the Multidisciplinary Association for Psychedelic Studies (MAPS) reported in 2025 that the regulatory rejection of the new drug application for MDMA-assisted therapy forced its public benefit subsidiary to reduce its workforce by 75% to conserve capital for renewed clinical trials. Such contractions underscore how regulatory strictness can rapidly strip capital from leading organizations, thereby freezing the pipeline of scalable treatments and discouraging future institutional investment in the sector.

Market Trends

The emerging shift toward short-duration psychedelic compounds is rapidly becoming a crucial trend, aiming to overcome the scalability limitations inherent in first-generation therapies that demand extended supervision. By developing molecules with shorter half-lives, researchers are creating treatments that can be administered within standard clinical operational hours, thereby lowering personnel costs and enhancing patient throughput. This innovation is demonstrated by recent clinical progress in novel serotonergic prodrugs, which seek to deliver prompt symptom relief without the six-to-eight-hour session durations linked to traditional psilocybin. Reunion Neuroscience reported in August 2025 positive topline results from its RECONNECT Phase 2 Clinical Trial, where its short-acting compound RE104 showed a statistically significant 23.0-point reduction in depression severity scores at Day 7, emphasizing its potential to streamline therapeutic delivery.

Simultaneously, the strategic entry of major pharmaceutical firms is redefining the competitive landscape, transitioning the sector from one dominated by biotech companies to one increasingly integrated with established industry giants. Large pharmaceutical corporations are progressively validating this field through high-value acquisitions and licensing agreements, intending to leverage their global commercialization capabilities for next-generation neuroplastogens. This trend signifies a maturing market where established players are actively securing promising assets to diversify their neuroscience portfolios. According to Fierce Biotech, in August 2025, AbbVie's agreement to acquire Gilgamesh's psychedelic program for up to $1.2 billion in total deal value represents a historic level of commitment from big pharma to this therapeutic class.

Key Market Players

• Jazz Pharmaceuticals PLC
• NeonMind Biosciences Inc.
• Cybin Inc.
• Pfizer Inc.
• Numinus Wellness Inc.
• Mind Medicine Inc.
• PharmaTher Holdings Ltd
• NRX Pharmaceuticals Inc.
• Seelos Therapeutics Inc.
• Revive Therapeutics Inc.

Report Scope

In this report, the Global Psychedelic Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Psychedelic Drug Market, By Drug Type

• Lysergic Acid Diethylamide
• Gamma Hydroxybutyric Acid
• Ketamine
• Psilocybin
• Others

Psychedelic Drug Market, By Application

• Treatment-Resistant Depression
• Opiate Addiction
• Post-Traumatic Stress Disorder
• Narcolepsy
• Panic Disorders
• Others

Psychedelic Drug Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Psychedelic Drug Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Psychedelic Drug Market.

Available Customizations:

Global Psychedelic Drug Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Psychedelic Drug Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
  • 5.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Psychedelic Drug Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Application
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Psychedelic Drug Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Psychedelic Drug Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Psychedelic Drug Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Distribution Channel

7. Europe Psychedelic Drug Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Application
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Psychedelic Drug Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Psychedelic Drug Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Psychedelic Drug Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Psychedelic Drug Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Psychedelic Drug Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Psychedelic Drug Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Application
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Psychedelic Drug Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Psychedelic Drug Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Psychedelic Drug Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Psychedelic Drug Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Psychedelic Drug Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Psychedelic Drug Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Application
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Psychedelic Drug Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Psychedelic Drug Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Psychedelic Drug Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Distribution Channel

10. South America Psychedelic Drug Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Application
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Psychedelic Drug Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Psychedelic Drug Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Psychedelic Drug Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Psychedelic Drug Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Jazz Pharmaceuticals PLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. NeonMind Biosciences Inc.
• 15.3. Cybin Inc.
• 15.4. Pfizer Inc.
• 15.5. Numinus Wellness Inc.
• 15.6. Mind Medicine Inc.
• 15.7. PharmaTher Holdings Ltd
• 15.8. NRX Pharmaceuticals Inc.
• 15.9. Seelos Therapeutics Inc.
• 15.10. Revive Therapeutics Inc.

16. Strategic Recommendations

17. About Us & Disclaimer